#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	4676	16S	1529	1470	99.93	16S.l15.c30.ctg.1	1703	429.9	0	.	n	.	0	C1450T	SNP	1450	1450	C	1391	1391	T	457	T	255	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	4676	16S	1529	1470	99.93	16S.l15.c30.ctg.1	1703	429.9	1	SNP	n	C1184T	0	.	.	1184	1184	C	1125	1125	C	502	C	278	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	8890	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3518	423.7	0	.	n	.	0	G1337A	SNP	1337	1337	G	1643	1643	A	423	A	244	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	8890	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3518	423.7	0	.	n	.	0	T1971C	SNP	1971	1971	T	2277	2277	C	486	C	277	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	8890	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3518	423.7	1	SNP	n	A2045G	0	.	.	2045	2045	A	2351	2351	A	534	A,G	312,1	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	8890	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3518	423.7	1	SNP	n	C2597T	0	.	.	2597	2597	C	2903	2903	C	527	C	298	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_Z_01426c	folP.WHO_Z_01426c	1	1	539	294	folP	852	852	99.88	folP.l15.c4.ctg.1	1476	33.7	0	.	p	.	0	E151K	NONSYN	451	453	GAA	695	697	AAA	53;53;53	A;A;A	28;30;30	.	.
folP.WHO_Z_01426c	folP.WHO_Z_01426c	1	1	539	294	folP	852	852	99.88	folP.l15.c4.ctg.1	1476	33.7	1	SNP	p	R228S	1	.	.	682	684	AGC	926	928	AGC	62;61;60	A;G;C	36;35;33	folP.WHO_Z_01426c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	854	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3266	44.9	1	SNP	p	S91F	0	.	.	271	273	TCC	573	575	TCC	71;71;71	T;C;C	38;41;41	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	854	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3266	44.9	1	SNP	p	D95G	0	.	.	283	285	GAC	585	587	GAC	69;69;70	G;A;C	40;39;36	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	854	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3266	44.9	1	SNP	p	D95N	0	.	.	283	285	GAC	585	587	GAC	69;69;70	G;A;C	40;39;36	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_Y_01506	mtrR.WHO_Y_01506	1	1	27	222	mtrR	633	633	100.0	mtrR.l15.c4.ctg.1	1044	35.6	1	SNP	p	G45D	0	.	.	133	135	GGC	264	266	GGC	66;66;66	G;G;C	34;35;34	mtrR.WHO_Y_01506:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	122	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c4.ctg.1	717	28.3	0	.	n	.	0	A197.	DEL	197	197	A	348	348	A	42	A	25	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	790	parC	2304	2304	99.91	parC.l15.c17.ctg.1	3000	43.1	1	SNP	p	D86N	0	.	.	256	258	GAC	432	434	GAC	70;70;70	G;A;C	39;40;41	parC.WHO_M_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	790	parC	2304	2304	99.91	parC.l15.c17.ctg.1	3000	43.1	1	SNP	p	S87W	0	.	.	259	261	AGT	435	437	AGT	68;70;67	A;G;T	40;40;40	parC.WHO_M_00204c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	790	parC	2304	2304	99.91	parC.l15.c17.ctg.1	3000	43.1	1	SNP	p	S87I	0	.	.	259	261	AGT	435	437	AGT	68;70;67	A;G;T	40;40;40	parC.WHO_M_00204c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	790	parC	2304	2304	99.91	parC.l15.c17.ctg.1	3000	43.1	1	SNP	p	S87R	0	.	.	259	261	AGT	435	437	AGT	68;70;67	A;G;T	40;40;40	parC.WHO_M_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	790	parC	2304	2304	99.91	parC.l15.c17.ctg.1	3000	43.1	1	SNP	p	S88P	0	.	.	262	264	TCC	438	440	TCC	68;69;67	T;C;C	40;38;41	parC.WHO_M_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	764	parE	1986	1986	100.0	parE.l15.c4.ctg.1	2488	54.9	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1514	1516	GGC	50;50;50	G;G;C	30;30;27	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.9.001	penA.9.001	1	1	283	852	penA	1749	1749	100.0	penA.l6.c17.ctg.1	2461	57.3	1	SNP	p	A311V	0	.	.	931	933	GCA	1183	1185	GCA	105;106;106	G,T;C;A	60,1;57;63	penA.9.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	283	852	penA	1749	1749	100.0	penA.l6.c17.ctg.1	2461	57.3	1	SNP	p	I312M	0	.	.	934	936	ATC	1186	1188	ATC	111;109;109	A;T;C	65;62;61	penA.9.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	283	852	penA	1749	1749	100.0	penA.l6.c17.ctg.1	2461	57.3	1	SNP	p	V316P	0	.	.	946	948	GTG	1198	1200	GTG	101;100;100	G;T;G	57;54;58	penA.9.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	283	852	penA	1749	1749	100.0	penA.l6.c17.ctg.1	2461	57.3	1	SNP	p	V316T	0	.	.	946	948	GTG	1198	1200	GTG	101;100;100	G;T;G	57;54;58	penA.9.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	283	852	penA	1749	1749	100.0	penA.l6.c17.ctg.1	2461	57.3	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1702	1704	ACC	48;48;46	A;C;C	28;29;29	penA.9.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	283	852	penA	1749	1749	100.0	penA.l6.c17.ctg.1	2461	57.3	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1756	1758	GCG	29;29;29	G;C;G	18;17;16	penA.9.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	283	852	penA	1749	1749	100.0	penA.l6.c17.ctg.1	2461	57.3	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1756	1758	GCG	29;29;29	G;C;G	18;17;16	penA.9.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	283	852	penA	1749	1749	100.0	penA.l6.c17.ctg.1	2461	57.3	1	SNP	p	G543S	0	.	.	1627	1629	GGC	1879	1881	GGC	32;35;35	G;G;C	19;21;21	penA.9.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	283	852	penA	1749	1749	100.0	penA.l6.c17.ctg.1	2461	57.3	1	SNP	p	G546S	0	.	.	1636	1638	GGC	1888	1890	GGC	30;30;30	G;G;C	17;16;17	penA.9.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	283	852	penA	1749	1749	100.0	penA.l6.c17.ctg.1	2461	57.3	1	SNP	p	L552S	0	.	.	1654	1656	CTG	1906	1908	CTG	33;33;33	C;T;G	16;14;17	penA.9.001:1:1:L552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	1512	ponA	2397	2397	100.0	ponA.l6.c4.ctg.1	3039	77.4	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1609	1611	CCG	48;48;48	C;C;G	27;31;27	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	398	porA	1146	1146	99.65	porA.l15.c4.ctg.1	1491	44.0	0	.	p	.	0	M83fs	FSHIFT	247	247	A	430	430	C	43	C	23	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	550	porB1b	1047	1047	99.43	porB1b.l15.c4.ctg.1	1509	61.1	0	.	p	.	0	N38E	NONSYN	112	114	AAT	299	301	GAA	72;71;72	G;A;A	43;44;44	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	550	porB1b	1047	1047	99.43	porB1b.l15.c4.ctg.1	1509	61.1	0	.	p	.	0	N134D	NONSYN	400	402	AAT	587	589	GAT	72;73;73	G;A;T	45;44;43	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	550	porB1b	1047	1047	99.43	porB1b.l15.c4.ctg.1	1509	61.1	0	.	p	.	0	P175S	NONSYN	523	525	CCA	710	712	TCA	77;77;77	T;C;A	43;45;46	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	550	porB1b	1047	1047	99.43	porB1b.l15.c4.ctg.1	1509	61.1	0	.	p	.	0	A218V	NONSYN	652	654	GCC	839	841	GTC	75;75;75	G;T;C	43;44;44	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	550	porB1b	1047	1047	99.43	porB1b.l15.c4.ctg.1	1509	61.1	1	SNP	p	G120K	1	.	.	358	360	AAG	545	547	AAG	78;78;78	A;A;G	48;47;48	porB1b.WHO_V_02265c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	550	porB1b	1047	1047	99.43	porB1b.l15.c4.ctg.1	1509	61.1	1	SNP	p	D121N	0	.	.	361	363	GAC	548	550	GAC	77;73;73	GACAAC,GAC;A;C,A	44,2;46;41,1	porB1b.WHO_V_02265c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	550	porB1b	1047	1047	99.43	porB1b.l15.c4.ctg.1	1509	61.1	1	SNP	p	A121D	1	.	.	361	363	GAC	548	550	GAC	77;73;73	GACAAC,GAC;A;C,A	44,2;46;41,1	porB1b.WHO_V_02265c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	539	2312	rpoB	4179	4179	99.98	rpoB.l15.c4.ctg.1	4523	85.8	1	SNP	p	H553N	1	H553N	NONSYN	1657	1659	CAT	1809	1811	AAT	114;114;114	A;A;T	68;64;66	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	196	rpsJ	312	312	100.0	rpsJ.l15.c30.ctg.1	935	36.5	1	SNP	p	V57M	1	.	.	169	171	ATG	411	413	ATG	67;67;71	A;T;G	38;40;42	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
